Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ: IDYA) announced management will participate in investor events the week of December 2, 2025.

Management appearances include a fireside chat with CEO Yujiro S. Hata at Citi's 2025 Global Healthcare Conference on Dec 2, 2025 at 9:00 AM ET and a fireside chat with CEO Yujiro S. Hata at the 8th Annual Evercore Healthcare Conference on Dec 3, 2025 at 10:50 AM ET.

A live audio webcast will be available via the IDEAYA Investors/Events webpage or through the conference host where permitted, with webcasts replayable for 30 days after the live event.

IDEAYA Biosciences (NASDAQ: IDYA) reported 3Q25 results and a business update on Nov 4, 2025. Key highlights: $1.14B cash, cash equivalents and marketable securities as of Sept 30, 2025, bolstered by a $210M upfront payment from an exclusive darovasertib license to Servier (outside U.S.) and collaboration revenue of $207.8M in 3Q25. IDEAYA expects funding into 2030.

Clinical milestones: Phase 2/3 OptimUM-02 median PFS data for darovasertib+crizotinib due by year-end 2025–1Q26; OptimUM-01 showed 21.1-month median OS and 7.0-month median PFS; IDE397 combo produced 57% ORR (4/7) in MTAP-deleted UC; IND clearance received for IDE892.

IDEAYA Biosciences (NASDAQ: IDYA) announced that on Oct 30, 2025 its Compensation Committee granted non-qualified stock options for an aggregate of 73,500 shares to two newly hired employees as inducement awards under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $31.60 per share (the closing price on the grant date), a 10-year term, and vest over four years (25% at the first anniversary of vesting commencement and the remaining 75% in equal monthly installments over the following three years), subject to continued service.

IDEAYA Biosciences (NASDAQ: IDYA) will participate in two investor relations events in November 2025: a Citi 2025 SMID Cap Biopharma Call Series fireside chat on Nov 6, 2025 at 12:00 PM ET, and a Jefferies Global Healthcare Conference fireside chat in London on Nov 18, 2025 at 1:00 PM GMT / 8:00 AM ET.

Both sessions feature CEO Yujiro S. Hata in discussion with industry analysts. Live audio webcasts will be available at the IDEAYA Investors/Events page and/or via the conference hosts, with replay access for 30 days where permitted.

IDEAYA Biosciences (NASDAQ: IDYA) presented positive Phase 2 data for neoadjuvant darovasertib in primary uveal melanoma at ESMO 2025 (data cut June 13, 2025).

Key results: 83% (78/94) of evaluable patients showed ocular tumor shrinkage; 57.1% eye preservation in enucleation‑recommended patients (42 completed local therapy); 95% eye preservation among patients with ≥20% tumor shrinkage. In plaque brachytherapy‑eligible patients, 70% (26/37) had reduced predicted radiation dose and 64.9% had lower predicted 3‑year vision‑loss risk. Darovasertib received FDA Breakthrough Therapy Designation for the neoadjuvant EN‑eligible setting.

IDEAYA Biosciences (NASDAQ: IDYA) reported Phase 1/2 OptimUM-01 results for darovasertib plus crizotinib in first-line metastatic uveal melanoma.

Key efficacy: median OS 21.1 months (n=44; median follow-up 25 months), median PFS 7.0 months, confirmed ORR 34% (14/41), mDOR 9.0 months, and DCR 90% (37/41). Safety was described as manageable; common TRAEs >30% included diarrhea, nausea, edema, vomiting, dermatitis, hypoalbuminemia, and fatigue, with no Grade ≥3 TRAEs >5% reported. IDEAYA is advancing a registrational Phase 2/3 OptimUM-02 trial and is targeting median PFS data by year-end 2025 to Q1 2026 to support a potential U.S. accelerated approval filing.

IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $25.69 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

IDEAYA Biosciences (Nasdaq: IDYA) has reported positive data from their Phase 1/2 trial combining IDE397 (MAT2A inhibitor) with Trodelvy® in MTAP-deletion urothelial cancer. The trial showed impressive results with a 57% overall response rate at Dose Level 2 (30mg IDE397 + 7.5mg/kg Trodelvy®) and 33% overall response rate at Dose Level 1 (15mg IDE397 + 10mg/kg Trodelvy®).

The study included 19 late-line patients, with 16 evaluable for efficacy. The combination demonstrated a manageable safety profile, with no treatment-related serious adverse events at the higher dose level. The data is particularly promising compared to historical Trodelvy monotherapy efficacy in metastatic UC, which showed 11-23% response rates.

The company plans to select the recommended Phase 2 dose by end of 2025, with the next update scheduled for H1 2026.

IDEAYA Biosciences (Nasdaq: IDYA) announced positive interim Phase 2 data for darovasertib in treating primary uveal melanoma (UM). The drug showed impressive results in the neoadjuvant setting, with 76% of patients achieving ≥20% ocular tumor shrinkage. Key findings include 48% of patients achieving ≥20% reduction in simulated radiation dose to key visual structures and 65% of patients showing visual improvement during treatment.

The Phase 2 OptimUM-09 trial evaluated 39 patients for safety and 21 for efficacy. Darovasertib demonstrated a manageable safety profile with mostly Grade 1 and 2 treatment-related adverse events, though approximately 10% experienced Grade 3 or higher events. The company has initiated a Phase 3 registration-enabling OptimUM-10 trial during Q2 2025.